Results 1 to 10 of about 96,641 (177)

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

New England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R. Kelley, P. Cassier, H. Klümpen, H. Chang, Li-Tzong Chen, J. Tabernero, Do-Youn Oh, A. Mahipal, M. Moehler, E. Mitchell, Y. Komatsu, Kunihiro Masuda, Daniel H Ahn, R. Epstein, A. Halim, Yao Fu, T. Salimi, V. Wacheck, Yaohua He, Mei Liu, K. Benhadji, J. Bridgewater   +29 more
semanticscholar   +1 more source

Locoregional Therapy for Intrahepatic Cholangiocarcinoma

Cancers, 2023
Simple Summary Intrahepatic cholangiocarcinoma is an aggressive primary liver cancer originating in the intrahepatic bile ducts. While surgical resection is the only curative treatment, many patients present with locally advanced, unresectable, or ...
Mackenzie Owen, M. Makary, E. Beal
semanticscholar   +1 more source

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

Ca, 2022
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially ...
D. Moris, M. Palta, Charles Kim, P. Allen, M. Morse, M. Lidsky   +5 more
semanticscholar   +1 more source

Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma

Nature Communications, 2022
Intrahepatic cholangiocarcinoma (iCCA) is a highly heterogeneous cancer with limited understanding of its classification and tumor microenvironment. Here, by performing single-cell RNA sequencing on 144,878 cells from 14 pairs of iCCA tumors and non ...
Guohe Song, Yang Shi, Lu Meng, Jiaqiang Ma, Siyuan Huang, Juan Zhang, Yingcheng Wu, Jiaxin Li, Youpei Lin, Shuaixi Yang, D. Rao, Yifei Cheng, Jian Lin, S. Ji, Yuming Liu, Shan Jiang, Xiaoliang Wang, Shu Zhang, A. Ke, Xiaoying Wang, Yanlong Cao, Yuan Ji, Jian Zhou, Jia Fan, Xiaoming Zhang, Ruibin Xi, Q. Gao   +26 more
semanticscholar   +1 more source

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications

Gut, 2022
Objective The diversity of the tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) has not been comprehensively assessed. We aimed to generate a novel molecular iCCA classifier that incorporates elements of the stroma, tumour and ...
Miguel A Martín-Serrano, Benjamin Kepecs, M. Torres‐Martín, Emily R Bramel, Philipp K. Haber, E. Merritt, Alexander Rialdi, Nesteene J Param, Mihoko Maeda, K. Lindblad, James K. Carter, M. Bárcena-Varela, V. Mazzaferro, M. Schwartz, Silvia Affò, R. Schwabe, A. Villanueva, E. Guccione, S. Friedman, A. Lujambio, A. Tocheva, J. Llovet, S. Thung, A. Tsankov, D. Sia   +24 more
semanticscholar   +1 more source

Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma

Liver Cancer, 2022
This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan.
S. Kubo, H. Shinkawa, Yoshinari Asaoka, T. Ioka, H. Igaki, N. Izumi, T. Itoi, M. Unno, M. Ohtsuka, T. Okusaka, M. Kadoya, M. Kudo, T. Kumada, N. Kokudo, M. Sakamoto, Y. Sakamoto, Hideyuki Sakurai, T. Takayama, O. Nakashima, Y. Nagata, E. Hatano, K. Harada, Takamichi Murakami, Masakazu Yamamoto   +23 more
semanticscholar   +1 more source

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma

Gut microbes, 2022
Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy with a high prevalence in China. This study aimed to characterize the ICC tissues’ bacterial metagenomics signature and explore its antitumor potential for cancer.
Xiaoqiang Chai, Jie Wang, Huanping Li, Chao Gao, Shuangqiu Li, Chuanyuan Wei, Jianhang Huang, Ying Tian, Jian Yuan, Jia-Cheng Lu, Dongmei Gao, Yi-Min Zheng, Cheng Huang, Jian Zhou, G. Shi, A. Ke, Feng Liu, Jia Fan, Jia-Bing Cai   +18 more
semanticscholar   +1 more source

Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach

Cancers, 2022
Simple Summary This review discusses multimodality treatment strategies for intrahepatic cholangiocarcinoma (iCC). Surgical resection remains the only potentially curative therapeutic option and the central cornerstone of treatment.
F. Krenzien, N. Nevermann, Alina Krombholz, C. Benzing, P. Haber, U. Fehrenbach, G. Lurje, U. Pelzer, J. Pratschke, M. Schmelzle, W. Schöning   +10 more
semanticscholar   +1 more source

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Clinical and Molecular Hepatology, 2022
Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently
Mina Komuta
semanticscholar   +1 more source

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Cancer Research, 2021
This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.
Xinyao Qiu, Shuai Yang, Shan Wang, Jianmin Wu, Bo Zheng, Kaiting Wang, Siyun Shen, Seogsong Jeong, Zhixuan Li, Yan-jing Zhu, Tong Wu, Xuan Wu, R. Wu, Weiwei Liu, Hong-Yang Wang, Lei Chen   +15 more
semanticscholar   +1 more source